Congratulations to Sarepta Therapeutics on receiving FDA's full approval of their gene therapy for ambulatory Duchenne muscular dystrophy (DMD) in patients four years or older. This is a critical milestone for patients with DMD and their loved ones, and it underscores the importance of accelerated approval as a potential path to get more cell and gene therapies to patients more quickly, especially when unmet needs are high and current treatments do not fully address them. We are excited to see this progress for patients, and within the field, as we work to realize the full potential of genetic medicines.
Congratulations!
Bridge Investment Group
1moExcellent!